drugset / Trial / NCT00708773
Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
Describe the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of irinotecan in cancer patients with advanced solid tumors with UGT1A1 6/6 and 6/7 genotypes.
Timeline
- Start
- 2006-02
- Primary completion
- 2016-08
- Completion
- 2016-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | — | Intravenous |
Indications
No indication recorded.